Endologix Stock Price, News & Analysis (NASDAQ:ELGX)

$5.26 -0.02 (-0.38 %)
(As of 11/20/2017 10:21 AM ET)
Previous Close$5.28
Today's Range$5.19 - $5.48
52-Week Range$4.08 - $7.91
Volume553,300 shs
Average Volume1.23 million shs
Market Capitalization$438.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69

About Endologix (NASDAQ:ELGX)

Endologix logoEndologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.


Industry, Sector and Symbol:
  • Industry: Medical Devices & Implants
  • Sub-Industry: Health Care Supplies
  • Sector: Healthcare
  • Symbol: NASDAQ:ELGX
  • CUSIP: 29266S10
  • Web: endologix.com
Debt:
  • Debt-to-Equity Ratio: 2.61%
  • Current Ratio: 2.90%
  • Quick Ratio: 2.11%
Sales & Book Value:
  • Annual Sales: $192.93 million
  • Price / Sales: 2.28
  • Book Value: $1.36 per share
  • Price / Book: 3.87
Profitability:
  • Trailing EPS: ($0.93)
  • Net Income: ($154,670,000.00)
  • Net Margins: -41.60%
  • Return on Equity: -52.18%
  • Return on Assets: -13.70%
Misc:
  • Employees: 782
  • Outstanding Shares: 83,450,000
 

Frequently Asked Questions for Endologix (NASDAQ:ELGX)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) announced its earnings results on Tuesday, August, 2nd. The medical instruments supplier reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). The medical instruments supplier earned $51 million during the quarter, compared to analysts' expectations of $46.30 million. Endologix had a negative return on equity of 52.18% and a negative net margin of 41.60%. The business's revenue was up 29.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.18) earnings per share. View Endologix's Earnings History.

Where is Endologix's stock going? Where will Endologix's stock price be in 2017?

9 brokers have issued 1-year target prices for Endologix's shares. Their predictions range from $4.00 to $10.00. On average, they expect Endologix's stock price to reach $6.17 in the next twelve months. View Analyst Ratings for Endologix.

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:

  • 1. Canaccord Genuity analysts commented, "Alimera reported 2Q17 Iluvien US sales of $8.1M which was above our estimate of." (8/4/2017)
  • 2. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (7/25/2017)

Are investors shorting Endologix?

Endologix saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 12,716,628 shares, a decrease of 13.1% from the October 13th total of 14,633,812 shares. Based on an average daily trading volume, of 422,136 shares, the days-to-cover ratio is presently 30.1 days. Currently, 16.8% of the company's shares are sold short.

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:

  • Daniel T. Lemaitre, Chairman of the Board (Age 63)
  • Robert D. Mitchell, President (Age 55)
  • John D. McDermott, Chief Executive Officer, Director (Age 57)
  • Vaseem Mahboob, Chief Financial Officer, Corporate Secretary (Age 48)
  • John Onopchenko, Chief Operating Officer (Age 59)
  • Michael V. Chobotov Ph.D., Chief Technology Officer (Age 56)
  • David M. Jennings, Vice President - Human Resources (Age 62)
  • Amanda L. DePalma, Vice President - Global Marketing (Age 45)
  • Meredith O. Huetter, Vice President - Global Medical Affairs (Age 43)
  • Michael P. Maszy, Vice President - Manufacturing (Age 40)

Who owns Endologix stock?

Endologix's stock is owned by a number of of institutional and retail investors. Top institutional investors include Cortina Asset Management LLC (1.00%), Schwab Charles Investment Management Inc. (0.40%), California State Teachers Retirement System (0.16%), Wells Fargo & Company MN (0.13%), JPMorgan Chase & Co. (0.13%) and Valeo Financial Advisors LLC (0.04%). Company insiders that own Endologix stock include Amanda L Depalma, Charles Steele Love, Dan Lemaitre, Gregory D Waller, Guido J Neels, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Who sold Endologix stock? Who is selling Endologix stock?

Endologix's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and California State Teachers Retirement System. View Insider Buying and Selling for Endologix.

Who bought Endologix stock? Who is buying Endologix stock?

Endologix's stock was purchased by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, JPMorgan Chase & Co., Valeo Financial Advisors LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy Endologix stock?

Shares of Endologix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of Endologix stock can currently be purchased for approximately $5.26.

How big of a company is Endologix?

Endologix has a market capitalization of $438.97 million and generates $192.93 million in revenue each year. The medical instruments supplier earns ($154,670,000.00) in net income (profit) each year or ($0.93) on an earnings per share basis. Endologix employs 782 workers across the globe.

How can I contact Endologix?

Endologix's mailing address is 2 Musick, IRVINE, CA 92618-1631, United States. The medical instruments supplier can be reached via phone at +1-949-5957200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  303 (Vote Underperform)
Total Votes:  598
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Endologix (NASDAQ:ELGX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 9 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.17 (17.24% upside)

Consensus Price Target History for Endologix (NASDAQ:ELGX)

Price Target History for Endologix (NASDAQ:ELGX)

Analysts' Ratings History for Endologix (NASDAQ:ELGX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017Canaccord GenuityReiterated RatingHold$5.00N/AView Rating Details
11/8/2017Stifel NicolausLower Price TargetHold$6.00 -> $5.50N/AView Rating Details
11/8/2017Royal Bank Of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
8/3/2017Oppenheimer Holdings, Inc.Set Price TargetHold$5.00HighView Rating Details
5/18/2017BMO Capital MarketsReiterated RatingHold$5.00HighView Rating Details
5/18/2017StephensDowngradeOverweight -> Equal Weight$6.00HighView Rating Details
5/18/2017BTIG ResearchDowngradeBuy -> Neutral$7.00HighView Rating Details
12/7/2016Leerink SwannReiterated RatingMarket Perform$11.00 -> $8.00N/AView Rating Details
12/4/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$14.00 -> $10.00N/AView Rating Details
11/16/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
8/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/AView Rating Details
2/22/2016Credit Suisse GroupLower Price TargetOutperform$16.00 -> $10.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Endologix (NASDAQ:ELGX)

Earnings by Quarter for Endologix (NASDAQ:ELGX)

Earnings History by Quarter for Endologix (NASDAQ ELGX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($0.18)($0.10)$47.58 million$48.60 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.24)($0.18)$41.15 million$42.60 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.19)($0.22)$48.69 million$47.46 millionViewListenView Earnings Details
11/1/2016Q316($0.15)($0.11)$51.83 million$52.12 millionViewN/AView Earnings Details
8/2/2016Q2($0.20)($0.20)$46.30 million$51.00 millionViewListenView Earnings Details
5/9/2016Q1($0.24)($0.25)$38.78 million$42.40 millionViewN/AView Earnings Details
2/22/2016Q4($0.16)($0.08)$39.97 million$39.20 millionViewListenView Earnings Details
10/26/2015Q315($0.14)($0.13)$38.12 million$38.20 millionViewListenView Earnings Details
8/3/2015Q215($0.13)($0.18)$39.47 million$39.50 millionViewN/AView Earnings Details
4/29/2015Q115($0.13)($0.14)$37.94 million$36.70 millionViewN/AView Earnings Details
2/25/2015Q414($0.10)($0.11)$38.10 million$38.80 millionViewN/AView Earnings Details
10/30/2014Q314($0.13)($0.13)$37.00 million$37.20 millionViewListenView Earnings Details
7/30/2014Q214($0.08)($0.06)$36.50 million$38.30 millionViewListenView Earnings Details
4/30/2014Q114($0.08)($0.08)$32.24 million$33.30 millionViewListenView Earnings Details
2/27/2014Q413($0.05)($0.05)$35.80 million$35.25 millionViewListenView Earnings Details
10/30/2013Q313($0.05)$0.01$32.47 million$33.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.06)($0.03)$33.94 million$34.00 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)($0.15)$29.26 million$29.80 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.03)($0.09)$29.03 million$29.22 millionViewN/AView Earnings Details
10/25/2012($0.04)($0.03)ViewN/AView Earnings Details
7/26/2012($0.04)($0.09)ViewN/AView Earnings Details
4/26/2012($0.06)($0.07)ViewN/AView Earnings Details
2/22/2012($0.05)($0.06)ViewN/AView Earnings Details
10/27/2011($0.05)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endologix (NASDAQ:ELGX)
2017 EPS Consensus Estimate: ($0.74)
2018 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.22)($0.22)
Q2 20172($0.18)($0.16)($0.17)
Q3 20172($0.16)($0.15)($0.16)
Q4 20172($0.22)($0.17)($0.20)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endologix (NASDAQ:ELGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endologix (NASDAQ ELGX)

Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 97.97%
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)

Insider Trades by Quarter for Endologix (NASDAQ ELGX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Dan LemaitreDirectorBuy22,522$4.43$99,772.46View SEC Filing  
5/19/2017Guido J NeelsDirectorBuy20,000$4.32$86,400.00View SEC Filing  
5/19/2017Robert D MitchellPresidentBuy2,200$4.32$9,504.00View SEC Filing  
12/14/2016John D McdermottCEOBuy10,000$6.67$66,700.00View SEC Filing  
12/14/2016Thomas F Zenty IIIDirectorBuy3,000$6.51$19,530.00View SEC Filing  
12/13/2016Vaseem MahboobCFOBuy20,000$6.25$125,000.00View SEC Filing  
11/18/2016Guido J NeelsDirectorBuy13,000$7.69$99,970.00View SEC Filing  
8/19/2016Jose A LimaVPSell4,710$11.68$55,012.80View SEC Filing  
8/5/2016Michael V ChobotovInsiderSell14,000$12.40$173,600.00View SEC Filing  
6/3/2016Gregory D WallerDirectorSell7,800$12.86$100,308.00View SEC Filing  
6/1/2016Amanda L DepalmaVPSell689$12.55$8,646.95View SEC Filing  
6/1/2016John D McdermottCEOSell6,116$12.55$76,755.80View SEC Filing  
6/1/2016Joseph A DejohnInsiderSell957$12.55$12,010.35View SEC Filing  
6/1/2016Robert D MitchellPresidentSell2,294$12.55$28,789.70View SEC Filing  
5/26/2016James Edward MachekVPSell6,500$12.76$82,940.00View SEC Filing  
1/26/2016Charles Steele LoveVPSell4,280$7.72$33,041.60View SEC Filing  
11/3/2015Guido J NeelsDirectorBuy11,000$9.32$102,520.00View SEC Filing  
11/3/2015Todd AbrahamVPBuy2,500$8.85$22,125.00View SEC Filing  
11/2/2015John D McdermottCEOBuy20,000$8.90$178,000.00View SEC Filing  
9/3/2015Jose A LimaVPSell1,923$12.60$24,229.80View SEC Filing  
5/26/2015Thomas WilderDirectorSell3,790$16.08$60,943.20View SEC Filing  
5/20/2015Jose A LimaVPSell1,872$16.75$31,356.00View SEC Filing  
4/6/2015Robert D MitchellPresidentSell45,000$17.33$779,850.00View SEC Filing  
12/12/2014Charles Steele LoveVPSell10,000$13.95$139,500.00View SEC Filing  
11/18/2014Charles Steele LoveVPBuy2,000$11.70$23,400.00View SEC Filing  
11/4/2014Guido J NeelsDirectorBuy10,000$11.21$112,100.00View SEC Filing  
11/4/2014John D McdermottCEOBuy25,000$11.25$281,250.00View SEC Filing  
8/4/2014Thomas WilderDirectorSell3,500$13.68$47,880.00View SEC Filing  
6/12/2014Robert D MitchellPresidentSell18,271$14.23$259,996.33View SEC Filing  
6/10/2014Robert D MitchellPresidentSell8,516$14.20$120,927.20View SEC Filing  
8/14/2013Stefan SchreckVPSell25,000$16.18$404,500.00View SEC Filing  
8/13/2013Stefan SchreckVPSell29,000$15.88$460,520.00View SEC Filing  
8/5/2013Gary SorsherVPSell12,483$15.98$199,478.34View SEC Filing  
8/5/2013John McdermottCEOSell165,000$16.00$2,640,000.00View SEC Filing  
8/2/2013Todd AbrahamVPSell9,994$15.90$158,904.60View SEC Filing  
8/1/2013John D McdermottCEOSell15,000$15.83$237,450.00View SEC Filing  
6/3/2013Thomas WilderDirectorSell22,500$13.25$298,125.00View SEC Filing  
5/28/2013Leonard M GreensteinVPSell1,253$14.01$17,554.53View SEC Filing  
12/28/2012Robert John KristCFOSell37,530$14.06$527,671.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Endologix (NASDAQ ELGX)

Source:
DateHeadline
Comparing Endologix (ELGX) and Its PeersComparing Endologix (ELGX) and Its Peers
www.americanbankingnews.com - November 20 at 5:16 AM
Endologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare ConferenceEndologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare Conference
finance.yahoo.com - November 14 at 6:41 PM
Endologix, Inc. (ELGX) Short Interest UpdateEndologix, Inc. (ELGX) Short Interest Update
www.americanbankingnews.com - November 12 at 4:30 AM
Endologix, Inc. – Value Analysis (NASDAQ:ELGX) : November 10, 2017Endologix, Inc. – Value Analysis (NASDAQ:ELGX) : November 10, 2017
finance.yahoo.com - November 10 at 7:16 PM
Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : November 9, 2017Endologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : November 9, 2017
finance.yahoo.com - November 10 at 12:05 PM
Oppenheimer Holdings Equities Analysts Increase Earnings Estimates for Endologix, Inc. (ELGX)Oppenheimer Holdings Equities Analysts Increase Earnings Estimates for Endologix, Inc. (ELGX)
www.americanbankingnews.com - November 10 at 7:47 AM
Oppenheimer Holdings Equities Analysts Increase Earnings Estimates for Endologix, Inc. (ELGX)Oppenheimer Holdings Equities Analysts Increase Earnings Estimates for Endologix, Inc. (ELGX)
www.americanbankingnews.com - November 10 at 7:47 AM
Equities Analysts Set Expectations for Endologix, Inc.s FY2017 Earnings (ELGX)Equities Analysts Set Expectations for Endologix, Inc.'s FY2017 Earnings (ELGX)
www.americanbankingnews.com - November 10 at 7:47 AM
Endologix, Inc. (ELGX) Forecasted to Earn Q1 2018 Earnings of ($0.16) Per ShareEndologix, Inc. (ELGX) Forecasted to Earn Q1 2018 Earnings of ($0.16) Per Share
www.americanbankingnews.com - November 9 at 11:46 AM
Canaccord Genuity Reiterates Hold Rating for Endologix, Inc. (ELGX)Canaccord Genuity Reiterates Hold Rating for Endologix, Inc. (ELGX)
www.americanbankingnews.com - November 8 at 7:44 PM
NasdaqGS Healthcare Industry: A Deep Dive Into Endologix Inc (ELGX)NasdaqGS Healthcare Industry: A Deep Dive Into Endologix Inc (ELGX)
finance.yahoo.com - November 8 at 6:07 AM
Endologix, Inc. to Host Earnings CallEndologix, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 6:07 AM
Endologix Reports Third Quarter 2017 Financial ResultsEndologix Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 6:07 AM
Endologix reports 3Q lossEndologix reports 3Q loss
finance.yahoo.com - November 8 at 6:07 AM
Edited Transcript of ELGX earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of ELGX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 6:07 AM
ELGX Crosses Above Average Analyst TargetELGX Crosses Above Average Analyst Target
www.thestreet.com - November 6 at 7:43 PM
Endologix, Inc. (ELGX) Receives Consensus Rating of "Hold" from BrokeragesEndologix, Inc. (ELGX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 1:32 AM
Obalon Therptcs (OBLN) vs. Endologix (ELGX) Head-To-Head SurveyObalon Therptcs (OBLN) vs. Endologix (ELGX) Head-To-Head Survey
www.americanbankingnews.com - November 2 at 9:38 PM
Zacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $47.21 MillionZacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $47.21 Million
www.americanbankingnews.com - November 2 at 11:02 AM
Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - November 2 at 12:19 AM
Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - November 1 at 7:19 PM
Endologix, Inc. (ELGX) Set to Announce Quarterly Earnings on TuesdayEndologix, Inc. (ELGX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 11:34 AM
Is Endologix Inc (ELGX) A Financially Sound Company?Is Endologix Inc (ELGX) A Financially Sound Company?
finance.yahoo.com - October 30 at 6:56 PM
ETFs with exposure to Endologix, Inc. : October 27, 2017ETFs with exposure to Endologix, Inc. : October 27, 2017
finance.yahoo.com - October 27 at 3:23 PM
Endologix (ELGX) Names John Onopchenko as COO - StreetInsider.comEndologix (ELGX) Names John Onopchenko as COO - StreetInsider.com
www.streetinsider.com - October 21 at 12:46 AM
What Does Endologix Inc’s (ELGX) Share Price Indicate?What Does Endologix Inc’s (ELGX) Share Price Indicate?
finance.yahoo.com - October 16 at 4:21 PM
Short Interest In Endologix Drops 12.2%Short Interest In Endologix Drops 12.2%
www.thestreet.com - October 11 at 7:48 PM
Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017 - Business Wire (press release)Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017 - Business Wire (press release)
www.businesswire.com - October 10 at 9:01 PM
Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017
finance.yahoo.com - October 10 at 9:01 PM
Endologix, Inc. (ELGX) Receives Hold Rating from Canaccord GenuityEndologix, Inc. (ELGX) Receives Hold Rating from Canaccord Genuity
www.americanbankingnews.com - October 9 at 3:16 PM
Endologix (ELGX) Announces IDE Approval for EVAS2 Confirmatory ... - StreetInsider.comEndologix (ELGX) Announces IDE Approval for EVAS2 Confirmatory ... - StreetInsider.com
www.streetinsider.com - October 7 at 4:44 AM
Endologix, Inc. (ELGX) Given a $6.00 Price Target at Stifel NicolausEndologix, Inc. (ELGX) Given a $6.00 Price Target at Stifel Nicolaus
www.americanbankingnews.com - October 6 at 8:32 PM
ECYT On A Roll, MannKind Delighted, DRRX Gains On Patent Deal, PTCT SlumpsECYT On A Roll, MannKind Delighted, DRRX Gains On Patent Deal, PTCT Slumps
www.finanznachrichten.de - October 4 at 10:20 AM
Endologix Extends Its Winning StreakEndologix Extends Its Winning Streak
www.benzinga.com - October 4 at 10:20 AM
ETFs with exposure to Endologix, Inc. : October 3, 2017ETFs with exposure to Endologix, Inc. : October 3, 2017
finance.yahoo.com - October 3 at 6:23 PM
Endologixs (ELGX) "Hold" Rating Reaffirmed at Canaccord GenuityEndologix's (ELGX) "Hold" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - October 1 at 5:14 PM
What Are The Drivers Of Endologix Inc’s (ELGX) Risks?What Are The Drivers Of Endologix Inc’s (ELGX) Risks?
finance.yahoo.com - September 30 at 7:33 PM
Endologix, FDA Delays Nellix EVAS in May, Guidance and Pipeline ReviewEndologix, FDA Delays Nellix EVAS in May, Guidance and Pipeline Review
finance.yahoo.com - September 28 at 9:41 AM
Endologix, Inc. (ELGX) Expected to Announce Quarterly Sales of $47.24 MillionEndologix, Inc. (ELGX) Expected to Announce Quarterly Sales of $47.24 Million
www.americanbankingnews.com - September 25 at 6:52 AM
Endologix, Inc. (ELGX) Expected to Announce Earnings of -$0.17 Per ShareEndologix, Inc. (ELGX) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - September 23 at 12:16 PM
ETFs with exposure to Endologix, Inc. : September 22, 2017ETFs with exposure to Endologix, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 5:19 PM
Endologix, Inc. :ELGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017Endologix, Inc. :ELGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
finance.yahoo.com - September 21 at 6:21 PM
Endologix (ELGX) Granted CE Mark Approval for Nellix EndoVascular Aneurysm Sealing System with Refined ... - StreetInsider.comEndologix (ELGX) Granted CE Mark Approval for Nellix EndoVascular Aneurysm Sealing System with Refined ... - StreetInsider.com
www.streetinsider.com - September 21 at 9:02 AM
Endologix Announces CE Mark Approval for the Nellix® EndoVascular Aneurysm Sealing System with the Refined Indications for UseEndologix Announces CE Mark Approval for the Nellix® EndoVascular Aneurysm Sealing System with the Refined Indications for Use
finance.yahoo.com - September 21 at 9:02 AM
Lombard Medical Appoints Jonathan Hornsby as Vice President, Sales & MarketingLombard Medical Appoints Jonathan Hornsby as Vice President, Sales & Marketing
www.businesswire.com - September 20 at 4:15 AM
Endologix, Inc. (ELGX) Given Consensus Rating of "Hold" by BrokeragesEndologix, Inc. (ELGX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 2:46 AM
Is There Now An Opportunity In Endologix Inc (ELGX)?Is There Now An Opportunity In Endologix Inc (ELGX)?
finance.yahoo.com - September 14 at 12:38 AM
Healthcare Stock Performance Review -- Glaukos, Endologix, Merit Medical Systems, and HTG Molecular DiagnosticsHealthcare Stock Performance Review -- Glaukos, Endologix, Merit Medical Systems, and HTG Molecular Diagnostics
www.bizjournals.com - September 12 at 7:00 PM
Endologix (ELGX) Reports Collaboration Agreements with Japan Lifeline for Development & Commercialization of ... - StreetInsider.comEndologix (ELGX) Reports Collaboration Agreements with Japan Lifeline for Development & Commercialization of ... - StreetInsider.com
www.streetinsider.com - September 11 at 11:52 PM
Endologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in JapanEndologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan
finance.yahoo.com - September 11 at 6:51 PM

Social Media

Financials

Chart

Endologix (NASDAQ ELGX) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.